Targeted Substance Delivery to the Mouse Brain via Infusion into the Internal Carotid Artery

Executive Industry Relevance

This microsurgical infusion technique enables targeted delivery of test substances to the mouse brain via the internal carotid artery, bypassing systemic circulation to enhance compound bioavailability and reduce off-target effects. The method supports mechanistic de-risking in early neuroscience drug discovery by allowing precise pharmacokinetic and pharmacodynamic evaluation of CNS-penetrant molecules. It provides a reproducible platform for evaluating blood-brain barrier penetration and brain parenchyma exposure, informing go/no-go decisions in lead optimization.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by delivering substances directly to brain tissue to assess target engagement and pathway modulation.
• Operational Value: Reduces systemic exposure variables, improving data clarity for target validation studies.
• Predictive Value: Supports assessment of CNS drug likelihood by confirming brain parenchyma delivery independent of systemic metabolism.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream compound screening by establishing consistent brain exposure conditions.
• Operational Value: Standardizes delivery parameters (e.g., infusion rate, volume) to improve assay reproducibility across studies.
• Scalability Value: Facilitates platform reuse for evaluating multiple substances under controlled vascular access conditions.

Translational & Preclinical Research

• Scientific Value: Maintains disease relevance by enabling substance delivery in a physiologically intact neurovascular system.
• Operational Value: Provides continuity from discovery to preclinical validation by using the same delivery route for dose-range finding.
• Risk Mitigation: Informs preclinical advancement decisions by quantifying brain exposure and reducing uncertainty in CNS efficacy.

Pipeline & Workflow Integration

The technique fits within the discovery continuum from early target validation through lead identification to preclinical efficacy testing, where controlled brain delivery is essential for evaluating CNS activity.

• Discovery Biology: Supports hypothesis testing by enabling localized substance delivery to clarify mechanism of action and pathway involvement.
• Screening: Enhances assay readiness through standardized, reproducible infusion procedures that yield quantitative brain exposure data.
• Analytics: Generates measurable outputs such as infusion volume, rate, and post-delivery substance recovery to compare delivery efficiency across compounds.
• Translational Research: Connects to preclinical continuity by allowing repeated dosing in the same model to assess time-dependent brain effects.
• Enterprise Reuse: Functions as a reusable vascular access platform for multiple substance evaluations, reducing model development time.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in CNS target validation by minimizing confounding systemic variables.
• Operational Value: Improves reproducibility through standardized suturing, clip placement, and infusion rate control.
• Strategic Value: Enhances capital efficiency by reducing failed CNS programs due to poor brain exposure.
• Portfolio Impact: Enables risk-adjusted prioritization of compounds based on verified brain delivery and target engagement.

Implementation Considerations

• Requires microsurgical expertise in vascular dissection, suture placement, and clip application under anesthesia.
• Depends on precision instrumentation including microdissection spring scissors, forceps, vessel clips, and capillary tubing.
• Necessitates cross-team standardization of infusion parameters (volume, rate, knot tension) to ensure inter-study consistency.
• Involves adaptation considerations for different substance viscosities and volumes to prevent leakage or occlusion.
• Limited by postoperative survival duration, which may restrict longitudinal studies without recovery optimization.

Biopharma FAQs